IL162028A0 - Alpha 2 delta ligands to treat tinnitus - Google Patents

Alpha 2 delta ligands to treat tinnitus

Info

Publication number
IL162028A0
IL162028A0 IL16202803A IL16202803A IL162028A0 IL 162028 A0 IL162028 A0 IL 162028A0 IL 16202803 A IL16202803 A IL 16202803A IL 16202803 A IL16202803 A IL 16202803A IL 162028 A0 IL162028 A0 IL 162028A0
Authority
IL
Israel
Prior art keywords
alpha
delta ligands
treat tinnitus
tinnitus
treat
Prior art date
Application number
IL16202803A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162028(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL162028A0 publication Critical patent/IL162028A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL16202803A 2002-01-31 2003-01-20 Alpha 2 delta ligands to treat tinnitus IL162028A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35363202P 2002-01-31 2002-01-31
PCT/IB2003/000232 WO2003063845A1 (en) 2002-01-31 2003-01-20 Alpha 2 delta ligands to treat tinnitus

Publications (1)

Publication Number Publication Date
IL162028A0 true IL162028A0 (en) 2005-11-20

Family

ID=27663234

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16202803A IL162028A0 (en) 2002-01-31 2003-01-20 Alpha 2 delta ligands to treat tinnitus

Country Status (16)

Country Link
US (2) US7026505B2 (enExample)
EP (1) EP1469841A1 (enExample)
JP (1) JP2005521664A (enExample)
KR (1) KR20040081478A (enExample)
CN (1) CN1625393A (enExample)
AU (1) AU2003201716B2 (enExample)
BR (1) BR0307411A (enExample)
CA (1) CA2474000A1 (enExample)
CL (1) CL2008000613A1 (enExample)
IL (1) IL162028A0 (enExample)
MX (1) MXPA04004105A (enExample)
NZ (1) NZ532624A (enExample)
PL (1) PL371944A1 (enExample)
TW (1) TW200306177A (enExample)
WO (1) WO2003063845A1 (enExample)
ZA (1) ZA200403069B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101506140B (zh) * 2006-08-24 2014-06-18 百时美施贵宝公司 环状11β-羟类固醇脱氢酶Ⅰ型抑制剂
WO2008060572A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101260063B (zh) * 2008-03-21 2013-06-19 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
CN1279667A (zh) * 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
WO1999031074A2 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
JP2002516312A (ja) 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
CZ300834B6 (cs) * 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage

Also Published As

Publication number Publication date
NZ532624A (en) 2007-05-31
ZA200403069B (en) 2005-04-22
CL2008000613A1 (es) 2008-11-07
US7026505B2 (en) 2006-04-11
US7138542B2 (en) 2006-11-21
JP2005521664A (ja) 2005-07-21
BR0307411A (pt) 2004-12-07
US20030176504A1 (en) 2003-09-18
PL371944A1 (en) 2005-07-11
AU2003201716B2 (en) 2008-04-17
CA2474000A1 (en) 2003-08-07
EP1469841A1 (en) 2004-10-27
US20060100281A1 (en) 2006-05-11
MXPA04004105A (es) 2004-11-29
CN1625393A (zh) 2005-06-08
WO2003063845A1 (en) 2003-08-07
KR20040081478A (ko) 2004-09-21
TW200306177A (en) 2003-11-16

Similar Documents

Publication Publication Date Title
ZA200500435B (en) 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands
AU2005102A (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
GB0113751D0 (en) Surface treatment
GB0028269D0 (en) Well treatment
IL157059A0 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL159376A0 (en) Acne treatment
PL370890A1 (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
IL158445A0 (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL162243A0 (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
AU2003212634A8 (en) Compounds useful in the treatment of cancer
PL363238A1 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
PL371944A1 (en) Alpha 2 delta ligands to treat tinnitus
PL377464A1 (pl) Aminoalkoksyindole jako ligandy receptora 5-HT6 do leczenia zaburzeń OUN
IL158448A0 (en) Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
GB0223570D0 (en) Surface treatment
GB0221438D0 (en) Processes and compounds
GB0221574D0 (en) Treatments
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
GB0130763D0 (en) Treatment methods
GB0221157D0 (en) Novel treatment
GB0229243D0 (en) Compounds and process
GB0203328D0 (en) Substrate treatment
AU2003248679A8 (en) Treating disease using radium-225